{"protocolSection":{"identificationModule":{"nctId":"NCT04534114","orgStudyIdInfo":{"id":"21170"},"secondaryIdInfos":[{"id":"2019-003927-39","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Bayer","class":"INDUSTRY"},"briefTitle":"Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug","officialTitle":"Factor XI LICA to Reduce Thrombotic Events in End-Stage Renal Disease Patients on Hemodialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of BAY 2976217","acronym":"RE-THINc ESRD"},"statusModule":{"statusVerifiedDate":"2023-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-09-04","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-01-24","type":"ACTUAL"},"completionDateStruct":{"date":"2022-05-12","type":"ACTUAL"},"studyFirstSubmitDate":"2020-08-20","studyFirstSubmitQcDate":"2020-08-30","studyFirstPostDateStruct":{"date":"2020-09-01","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-05-06","resultsFirstSubmitQcDate":"2023-06-14","resultsFirstPostDateStruct":{"date":"2023-07-03","type":"ACTUAL"},"dispFirstSubmitDate":"2023-01-12","dispFirstSubmitQcDate":"2023-06-14","dispFirstPostDateStruct":{"date":"2023-07-03","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-06-14","lastUpdatePostDateStruct":{"date":"2023-07-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bayer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Patients whose kidneys are no longer able to work as they should and require treatment to filter wastes from the blood (hemodialysis) are at high risk for blood clots that form in blood vessels (thrombosis) blocking blood flow that causes heart attacks, strokes, and other life-threatening conditions. BAY2976217 is under clinical development for prevention of thrombosis. The goal of the study is to learn more about the safety of BAY2976217, how it is tolerated and the way the body absorbs, distributes and gets rid of the study dug given as multiple doses in participants with renal impairment who require hemodialysis."},"conditionsModule":{"conditions":["End Stage Renal Disease Requiring Hemodialysis"],"keywords":["End stage renal disease (ESRD)","Hemodialysis (HD)","Thrombotic Events"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":307,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pooled Placebo","type":"PLACEBO_COMPARATOR","description":"Participants received subcutaneous treatment with matching placebo.","interventionNames":["Drug: Placebo"]},{"label":"40 mg BAY2976217","type":"EXPERIMENTAL","description":"Participants received subcutaneous treatment with 40 mg BAY2976217.","interventionNames":["Drug: Fesomersen sodium (BAY2976217)"]},{"label":"80 mg BAY2976217","type":"EXPERIMENTAL","description":"Participants received subcutaneous treatment with 80 mg BAY2976217.","interventionNames":["Drug: Fesomersen sodium (BAY2976217)"]},{"label":"120 mg BAY2976217","type":"EXPERIMENTAL","description":"Participants received subcutaneous treatment with 120 mg BAY2976217.","interventionNames":["Drug: Fesomersen sodium (BAY2976217)"]}],"interventions":[{"type":"DRUG","name":"Fesomersen sodium (BAY2976217)","description":"Study intervention will be injected subcutaneously.","armGroupLabels":["120 mg BAY2976217","40 mg BAY2976217","80 mg BAY2976217"],"otherNames":["Factor XI LICA"]},{"type":"DRUG","name":"Placebo","description":"Matching placebo to BAY2976217 will be injected subcutaneously.","armGroupLabels":["Pooled Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of Composite of Major Bleeding (MB) and Clinically-relevant Non-major Bleeding (CRNMB) During the Main Treatment Period and Within the On-treatment Time Window, as Assessed by Blinded Central Independent Adjudication Committee (CIAC)","description":"MB is defined as symptomatic bleeding and: 1) Fatal bleeding, and/or; 2) Bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or; 3) Bleeding causing a fall in hemoglobin level of 20 g/L (2.0 g/dL) (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells. CRNMB is defined as any sign or symptom of hemorrhage that does not fit the criteria for the ISTH definition of major bleeding but does meet at least one of the following criteria: 1) Requiring medical intervention by a healthcare professional; 2) Leading to hospitalization or increased level of care; 3) Prompting a face-to-face evaluation. n/100 person-years: number of subjects with incident events divided by the cumulative at-risk time in the reference population, where a subject is no longer at risk once an incident event occurred.","timeFrame":"Up to 24 weeks"}],"secondaryOutcomes":[{"measure":"Incidence of Composite of MB and CRNMB During the Main and Extended Treatment Periods and Within the On-treatment Time Window, as Assessed by Blinded CIAC","description":"MB is defined as symptomatic bleeding and: 1) Fatal bleeding, and/or; 2) Bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or; 3) Bleeding causing a fall in hemoglobin level of 20 g/L (2.0 g/dL) (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells. CRNMB is defined as any sign or symptom of hemorrhage that does not fit the criteria for the ISTH definition of major bleeding but does meet at least one of the following criteria: 1) Requiring medical intervention by a healthcare professional; 2) Leading to hospitalization or increased level of care; 3) Prompting a face-to-face evaluation. n/100 person-years: number of subjects with incident events divided by the cumulative at-risk time in the reference population, where a subject is no longer at risk once an incident event occurred.","timeFrame":"Up to 48 weeks"},{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Main Treatment Period and Within the On-treatment Time Window and Their Severity","description":"TEAEs were analyzed during the on-treatment time window within the main treatment period in the safety analysis set (SAF). Data observed from the randomization date until the end of the main treatment period. TEAEs were defined as events occurring after first study intervention administration and up to 20 weeks after last study intervention administration.","timeFrame":"Up to 24 weeks"},{"measure":"Number of Participants With TEAEs During the Main and Extended Treatment Periods and Within the On-treatment Time Window and Their Severity","description":"TEAEs were analyzed during during main and extended treatment periods in the safety analysis set (SAF). Data observed from the randomization date until the end of the extension treatment period. TEAEs were defined as events occurring after first study intervention administration and up to 20 weeks after last study intervention administration.","timeFrame":"Up to 48 weeks"},{"measure":"Number of Participants With TEAEs During the Main and Extended Treatment Periods and Until 20 Weeks After the Last Study Intervention Dose and Their Severity","description":"TEAEs occurring from first study intervention intake until 20 weeks after last study intervention intake.","timeFrame":"Up to 48 weeks"},{"measure":"Trough Concentrations (Ctrough) of Three Dose Levels of Fesomersen","description":"Trough (pre-dose) fesomersen-equivalent plasma concentrations (Ctrough) for 3 dose levels of fesomersen were summarized descriptively by dose level and visit: Visit 12, Visit 14, Visit 16, Visit 18 (main treatment period). Ctrough was not measured for the placebo group.","timeFrame":"At visits V12 (Day 57), V14 (Day 85), V16 (Day 113), V18 (Day 141)"},{"measure":"Maximum Change in FXI (Coagulation Factor XI) Antigen Levels During the Main Treatment Period","description":"The secondary endpoint of change in FXI antigen levels during the main treatment period was an optional secondary endpoint only as mentioned in the integrated clinical protocol amendment version 3.0 and was not analyzed in this study as the FXI activity assay is sufficient to describe the effect on FXI level in plasma.","timeFrame":"Up to 24 weeks"},{"measure":"Maximum Change in FXI Activity Levels During the Main Treatment Period","description":"The FXIa activity was measured by a fluorogenic activated FXIa activity (AXIA) assay. Absolute change from baseline at each visit until Visit 22 (Day 169) are reported.","timeFrame":"Baseline, Days 1 (Pre-Dose and 5 hours post-dose), 2, 8, 15, 22, 29 (Pre-dose and 5 hours post-dose), 43, 57 (Pre-dose), 71, 85 (Pre-dose), 113 (Pre-dose), 141 (Pre-dose),148, 155, 162, and 169 (Pre-dose)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant must be at least 18 years of age at the time of signing the informed consent form (ICF)\n* Participants with ESRD on hemodialysis (HD) for ≥3 months at the time of signing of the ICF, receiving dialysis at least 9 hours a week and stable in the view of the investigator\n* Male or female (contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies)\n* Capable of giving signed ICF as described in the Protocol, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol\n\nExclusion Criteria:\n\n* Participants receiving antiplatelet therapy except daily acetylsalicylic acid (ASA) ≤ 150 mg/day\n* Participants receiving anticoagulation in therapeutic doses, other than standard anticoagulation during the hemodialysis procedure\n* Known inherited bleeding disorder e.g. von-Willebrand disease or Hemophilia A, B or C\n* Recent (\\<6 months before screening) clinically significant bleeding, or at high risk of bleeding (in the judgement of the investigator)\n* Recent (\\<3 months before screening) thromboembolic event, e.g. acute coronary syndrome, stroke, or Venous thromboembolism (except dialysis access thrombosis)\n* Recent (\\<3 months before screening) major surgery or scheduled major surgery during participation in the study\n* Scheduled living donor renal transplant during study participation\n* Known Hepatitis B or C\n* Known HIV with recent documented detectable viral load (\\<3 months before screening)\n* Persistent heart failure as classified by the New York Heart Association classification of 3 or higher\n* Life expectancy less than 6 months\n* Sustained uncontrolled hypertension (persistent measurements of diastolic blood pressure ≥ 100 mmHg, and/or systolic blood pressure ≥ 180 mmHg)\n* Hepatic disease associated with either: coagulopathy leading to a clinically relevant bleeding risk, or ALT \\> 3x ULN, or total bilirubin \\>2x ULN with direct bilirubin \\> 20% of the total\n* Hb \\< 9.0 g/dL at screening\n* Platelet count \\< 120,000 mm\\^3 at screening\n* Known hypersensitivity to the investigational drug or to inactive constituents of the study intervention\n* Active malignancy requiring treatment during study participation (except non-melanoma skin cancer, or cervical carcinoma in situ)\n* Participation in a study with an investigational medicinal product within 30 days or within 5 half-lives of the previous administered drug, whichever is longer, prior to the screening/observational period (Note: Participants from previous BAY2306001/ISIS 416858 and BAY2976217/ ION 957943 studies are eligible)\n* Any other conditions, which, in the opinion of the investigator or Sponsor would make the subject unsuitable for inclusion\n* Confirmed pregnancy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Fresenius Kidney Care Clovis","city":"Clovis","state":"California","zip":"93611","country":"United States","geoPoint":{"lat":36.82523,"lon":-119.70292}},{"facility":"Desert Cities Dialysis-Amethyst & Desert Cities Dialysis","city":"Victorville","state":"California","zip":"92392","country":"United States","geoPoint":{"lat":34.53611,"lon":-117.29116}},{"facility":"Davita East Ft. Lauderdale Dialysis Center","city":"Fort Lauderdale","state":"Florida","zip":"33316","country":"United States","geoPoint":{"lat":26.12231,"lon":-80.14338}},{"facility":"Fresenius Kidney Care St. Louis Regional Dialysis","city":"Saint Ann","state":"Missouri","zip":"63074","country":"United States","geoPoint":{"lat":38.72727,"lon":-90.38317}},{"facility":"Chromalloy Dialysis Center","city":"Saint Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Fresenius Medical Care - Fire Mesa Dialysis Unit","city":"Las Vegas","state":"Nevada","zip":"89128","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"DaVita Northwest Medical Center Dialysis","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"San Antonio Kidney Disease Center Physicians Group, PLLC","city":"San Antonio","state":"Texas","zip":"78258","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Salem VA Medical Center","city":"Salem","state":"Virginia","zip":"24153","country":"United States","geoPoint":{"lat":37.29347,"lon":-80.05476}},{"facility":"OL Vrouwziekenhuis - Campus Aalst","city":"Aalst","zip":"9300","country":"Belgium","geoPoint":{"lat":50.93604,"lon":4.0355}},{"facility":"UZ Brussel","city":"Bruxelles - Brussel","zip":"1090","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"UZ Antwerpen","city":"Edegem","zip":"2650","country":"Belgium","geoPoint":{"lat":51.15662,"lon":4.44504}},{"facility":"Regionaal ZH Jan Yperman Campus Mariaziekenhuis","city":"Ieper","zip":"8900","country":"Belgium","geoPoint":{"lat":50.85114,"lon":2.88569}},{"facility":"First Dialysis Services Bulgaria Ead","city":"Montana","zip":"3400","country":"Bulgaria","geoPoint":{"lat":43.4125,"lon":23.225}},{"facility":"MHAT Samokov","city":"Samokov","zip":"2000","country":"Bulgaria","geoPoint":{"lat":42.337,"lon":23.5528}},{"facility":"MHAT \"Knyaginya Klementina - Sofia\"EAD","city":"Sofia","zip":"1233","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"MHAT National Cardiology Hospital EAD","city":"Sofia","zip":"1309","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Etobicoke General Hospital","city":"Etobicoke","state":"Ontario","zip":"M9V 1R8","country":"Canada","geoPoint":{"lat":43.65421,"lon":-79.56711}},{"facility":"St. Joseph's Healthcare - Hamilton","city":"Hamilton","state":"Ontario","zip":"L8N 4A6","country":"Canada","geoPoint":{"lat":43.25011,"lon":-79.84963}},{"facility":"Lakeridge Health-Oshawa","city":"Oshawa","state":"Ontario","zip":"L1G 2B9","country":"Canada","geoPoint":{"lat":43.90012,"lon":-78.84957}},{"facility":"Unity Health Toronto: St. Michael's Hospital","city":"Toronto","state":"Ontario","zip":"M5B 1W8","country":"Canada","geoPoint":{"lat":43.70011,"lon":-79.4163}},{"facility":"Centre de services ambulatoires de dialyse de Gaspé","city":"Montreal","state":"Quebec","zip":"H2T 3B3","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"CHU de Québec-Université Laval","city":"Quebec","zip":"G1J 1Z4","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"Nemocnice Frydek-Mistek","city":"Frydek-Mistek","zip":"738 01","country":"Czechia","geoPoint":{"lat":49.68333,"lon":18.35}},{"facility":"Klatovska nemocnice","city":"Klatovy","zip":"339 01","country":"Czechia","geoPoint":{"lat":49.39552,"lon":13.29505}},{"facility":"Fresenius Medical Care - DS, s.r.o.","city":"Melnik","zip":"276 01","country":"Czechia","geoPoint":{"lat":50.3505,"lon":14.47411}},{"facility":"Oblastni nemocnice Mlada Boleslav","city":"Mlada Boleslav","zip":"293 50","country":"Czechia","geoPoint":{"lat":50.41135,"lon":14.90318}},{"facility":"DaVita Clinical Research Deutschland GmbH","city":"Duesseldorf","state":"Nordrhein-Westfalen","zip":"40210","country":"Germany","geoPoint":{"lat":51.22172,"lon":6.77616}},{"facility":"DaVita Clinical Resarch Germany GmbH","city":"Geilenkirchen","state":"Nordrhein-Westfalen","zip":"52511","country":"Germany","geoPoint":{"lat":50.96745,"lon":6.11763}},{"facility":"Universitätsklinikum Schleswig-Holstein (UKSH)","city":"Kiel","state":"Schleswig-Holstein","zip":"24105","country":"Germany","geoPoint":{"lat":54.32133,"lon":10.13489}},{"facility":"University General Hospital of Heraklion","city":"Heraklion","zip":"711 10","country":"Greece","geoPoint":{"lat":35.32787,"lon":25.14341}},{"facility":"University General Hospital of Patra","city":"Patra","zip":"26504","country":"Greece","geoPoint":{"lat":38.24444,"lon":21.73444}},{"facility":"PAPANIKOLAOU General Hospital Thessaloniki","city":"Pilea Chortiatis","zip":"57010","country":"Greece"},{"facility":"Bacs-Kiskun Megyei Korhaz","city":"Kalocsa","zip":"6300","country":"Hungary","geoPoint":{"lat":46.52639,"lon":18.98583}},{"facility":"SZTE ÁOK Szent Györgyi Albert Klinikai Kozpont","city":"Szeged","zip":"6720","country":"Hungary","geoPoint":{"lat":46.253,"lon":20.14824}},{"facility":"Matsunami General Hospital","city":"Hashima-gun","state":"Gifu","zip":"501-6062","country":"Japan"},{"facility":"Sapporo Tokushukai Hospital","city":"Sapporo","state":"Hokkaido","zip":"004-0041","country":"Japan","geoPoint":{"lat":43.06667,"lon":141.35}},{"facility":"Ibaraki Prefectural Central Hospital","city":"Kasama","state":"Ibaraki","zip":"309-1793","country":"Japan","geoPoint":{"lat":36.38333,"lon":140.26667}},{"facility":"Public Central Hospital of Matto Ishikawa","city":"Hakusan","state":"Ishikawa","zip":"924-8588","country":"Japan"},{"facility":"Shonan Fujisawa Tokushukai Hospital","city":"Fujisawa","state":"Kanagawa","zip":"251-0041","country":"Japan","geoPoint":{"lat":35.34926,"lon":139.47666}},{"facility":"Hanyu General Hospital","city":"Hanyu","state":"Saitama","zip":"348-0045","country":"Japan","geoPoint":{"lat":36.16667,"lon":139.53333}},{"facility":"Medical corporation association Shunshin-kai Inage hospital","city":"Chiba","zip":"263-0043","country":"Japan","geoPoint":{"lat":35.6,"lon":140.11667}},{"facility":"The Catholic University of Korea, Incheon St.Mary's Hospital","city":"Incheon","state":"Incheon Gwang''yeogsi","zip":"21431","country":"Korea, Republic of","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"Yeouido St. Mary's Hospital","city":"Seoul","state":"Seoul Teugbyeolsi","zip":"150-713","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Daugavpils Regional Hospital","city":"Daugavpils","zip":"LV-5417","country":"Latvia","geoPoint":{"lat":55.88333,"lon":26.53333}},{"facility":"Liepaja Regional Hospital","city":"Liepaja","zip":"LV-3414","country":"Latvia","geoPoint":{"lat":56.51667,"lon":21.01667}},{"facility":"P. Stradins Clinical University Hospital","city":"Riga","zip":"LV-1002","country":"Latvia","geoPoint":{"lat":56.946,"lon":24.10589}},{"facility":"Vidzemes Hospital","city":"Valmiera","zip":"LV-4201","country":"Latvia","geoPoint":{"lat":57.54108,"lon":25.42751}},{"facility":"High Technology Center Clinic 1","city":"Moscow","zip":"125466","country":"Russian Federation","geoPoint":{"lat":55.75222,"lon":37.61556}},{"facility":"Limited Liability Company \"Nefroline-Novosibirsk\"","city":"Novosibirsk","zip":"630064","country":"Russian Federation","geoPoint":{"lat":55.0415,"lon":82.9346}},{"facility":"LLC Frezenius Nefrocare","city":"Penza","zip":"440034","country":"Russian Federation","geoPoint":{"lat":53.20066,"lon":45.00464}},{"facility":"LLC Dialysis center","city":"Podolsk","zip":"142110","country":"Russian Federation","geoPoint":{"lat":55.42419,"lon":37.55472}},{"facility":"Nikiforov All-Russian Center of Emergency and Radiation Med","city":"Saint-Petersburg","zip":"197374","country":"Russian Federation","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Botkin clinical infectious diseases hospital","city":"St. Petersburg","zip":"195067","country":"Russian Federation","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"LLC B. Brown Avitum Russland Clinics","city":"St. Petersburg","zip":"196247","country":"Russian Federation","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"State Budgetary Healthcare Institution City Hospital #26","city":"St. Petersburg","zip":"196247","country":"Russian Federation","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Hospital Principe de Asturias","city":"Alcalá de Henares","state":"Madrid","zip":"28805","country":"Spain","geoPoint":{"lat":40.48205,"lon":-3.35996}},{"facility":"Hospital Universitari de Bellvitge | Bellvitge Biomedical Research Institute - Cardiology - AF, Stroke Prevention","city":"Barcelona","zip":"08907","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Clínic i Provincial de Barcelona","city":"Barcelona","zip":"8036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitario Virgen de las Nieves|Nefrologia","city":"Granada","zip":"18014","country":"Spain","geoPoint":{"lat":37.18817,"lon":-3.60667}},{"facility":"Hospital Universitari i Politècnic La Fe | Nefrología","city":"Valencia","zip":"46026","country":"Spain","geoPoint":{"lat":39.46975,"lon":-0.37739}},{"facility":"Chi Mei Medical Center","city":"Tainan","zip":"710","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"Taipei Medical University Hospital","city":"Taipei","zip":"110","country":"Taiwan","geoPoint":{"lat":25.04776,"lon":121.53185}},{"facility":"Medical Center Fresenius Medical Care Ukraine, LLC","city":"Chernigiv","zip":"14034","country":"Ukraine"},{"facility":"Kyiv City Center of Nephrology and Dialysis","city":"Kyiv","zip":"01023","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Kyiv Regional Clinical Hospital","city":"Kyiv","zip":"04107","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Regional Clinical Hospital - Odessa","city":"Odesa","zip":"65025","country":"Ukraine","geoPoint":{"lat":46.47747,"lon":30.73262}},{"facility":"Ternopil Regional Clinical Hospital","city":"Ternopil","zip":"46002","country":"Ukraine","geoPoint":{"lat":49.55589,"lon":25.60556}},{"facility":"Zaporizhia Municipal Clinical Hospital No.10","city":"Zaporizhzhya","zip":"69001","country":"Ukraine","geoPoint":{"lat":50.60727,"lon":31.78792}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.","url":"https://clinicaltrials.bayer.com/"},{"label":"Click here to find information about studies related to Bayer AG products conducted in Europe.","url":"http://www.clinicaltrialsregister.eu/"}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"There are no current plans to share data. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal."}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"From 359 participants screened, 51 participants were screening failure and a total of 308 participants were randomized and 307 were treated either with fesomersen or placebo.","recruitmentDetails":"Study was conducted at 69 study centers in 15 countries between 04-SEP-2020 (first participant first visit) and 12-MAY-2022 (last participant last visit).","groups":[{"id":"FG000","title":"Fesomersen 40 mg","description":"Participants received monthly subcutaneous treatment with 40 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"FG001","title":"Fesomersen 80 mg","description":"Participants received monthly subcutaneous treatment with 80 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"FG002","title":"Fesomersen 120 mg","description":"Participants received monthly subcutaneous treatment with 120 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"FG003","title":"Placebo","description":"Participants received monthly subcutaneous treatment with matching placebo to fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."}],"periods":[{"title":"Main Treatment Period","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"77"},{"groupId":"FG001","numSubjects":"79"},{"groupId":"FG002","numSubjects":"76"},{"groupId":"FG003","numSubjects":"75"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"67"},{"groupId":"FG001","numSubjects":"66"},{"groupId":"FG002","numSubjects":"64"},{"groupId":"FG003","numSubjects":"61"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"14"}]}],"dropWithdraws":[{"type":"COVID-19 pandemic: Participant decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"COVID-19 pandemic: Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"COVID-19 pandemic: Adverse event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"COVID-19 pandemic: withdrawal following protocol","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Other reason","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Participant decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Protocol-specified withdrawal criterion met","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"6"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"}]}]},{"title":"Extension Treatment Period","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"62"},{"groupId":"FG001","numSubjects":"61"},{"groupId":"FG002","numSubjects":"63"},{"groupId":"FG003","numSubjects":"58"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"59"},{"groupId":"FG001","numSubjects":"57"},{"groupId":"FG002","numSubjects":"62"},{"groupId":"FG003","numSubjects":"53"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"5"}]}],"dropWithdraws":[{"type":"COVID-19 pandemic: Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"COVID-19 pandemic: withdrawal following protocol","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Other reason","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Protocol-specified Withdrawal Criterion Met","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Fesomersen 40 mg","description":"Participants received monthly subcutaneous treatment with 40 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"BG001","title":"Fesomersen 80 mg","description":"Participants received monthly subcutaneous treatment with 80 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"BG002","title":"Fesomersen 120 mg","description":"Participants received monthly subcutaneous treatment with 120 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"BG003","title":"Placebo","description":"Participants received monthly subcutaneous treatment with matching placebo to fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"79"},{"groupId":"BG002","value":"76"},{"groupId":"BG003","value":"75"},{"groupId":"BG004","value":"307"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60.4","spread":"13.2"},{"groupId":"BG001","value":"58.0","spread":"14.4"},{"groupId":"BG002","value":"57.7","spread":"13.3"},{"groupId":"BG003","value":"58.6","spread":"11.9"},{"groupId":"BG004","value":"58.7","spread":"13.2"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"30"},{"groupId":"BG003","value":"22"},{"groupId":"BG004","value":"107"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"46"},{"groupId":"BG003","value":"53"},{"groupId":"BG004","value":"200"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"12"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"74"},{"groupId":"BG001","value":"73"},{"groupId":"BG002","value":"75"},{"groupId":"BG003","value":"72"},{"groupId":"BG004","value":"294"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"44"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"8"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"62"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"61"},{"groupId":"BG003","value":"61"},{"groupId":"BG004","value":"254"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Composite of Major Bleeding (MB) and Clinically-relevant Non-major Bleeding (CRNMB) During the Main Treatment Period and Within the On-treatment Time Window, as Assessed by Blinded Central Independent Adjudication Committee (CIAC)","description":"MB is defined as symptomatic bleeding and: 1) Fatal bleeding, and/or; 2) Bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or; 3) Bleeding causing a fall in hemoglobin level of 20 g/L (2.0 g/dL) (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells. CRNMB is defined as any sign or symptom of hemorrhage that does not fit the criteria for the ISTH definition of major bleeding but does meet at least one of the following criteria: 1) Requiring medical intervention by a healthcare professional; 2) Leading to hospitalization or increased level of care; 3) Prompting a face-to-face evaluation. n/100 person-years: number of subjects with incident events divided by the cumulative at-risk time in the reference population, where a subject is no longer at risk once an incident event occurred.","populationDescription":"Safety analysis set (SAF) includes all randomized participants who received at least one dose of the study intervention according to actual treatment arm received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"n/100 person-years","timeFrame":"Up to 24 weeks","groups":[{"id":"OG000","title":"Fesomersen 40 mg","description":"Participants received monthly subcutaneous treatment with 40 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG001","title":"Fesomersen 80 mg","description":"Participants received monthly subcutaneous treatment with 80 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG002","title":"Fesomersen 120 mg","description":"Participants received monthly subcutaneous treatment with 120 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG003","title":"Placebo","description":"Participants received monthly subcutaneous treatment with matching placebo to fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"76"},{"groupId":"OG003","value":"75"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","lowerLimit":"2.5","upperLimit":"18.9"},{"groupId":"OG001","value":"9.1","lowerLimit":"2.5","upperLimit":"19.1"},{"groupId":"OG002","value":"6.1","lowerLimit":"1.1","upperLimit":"14.5"},{"groupId":"OG003","value":"9.7","lowerLimit":"2.7","upperLimit":"20.4"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","nonInferiorityComment":"Fesomersen groups were compared to the placebo group using two-sided log-rank tests. Due to the exploratory nature of these analyses, no multiplicity adjustment was done. Cause-specific hazard ratio and corresponding 2-sided 95% confidence intervals, comparing the hazards for the event-of-interest in each of the Fesomersen groups with the placebo group were estimated based on three separate cause-specific Cox proportional hazards models as exploratory analysis.","pValue":"0.944","statisticalMethod":"Log Rank","paramType":"Cause specific Hazard ratio","paramValue":"0.94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.19","ciUpperLimit":"4.68"},{"groupIds":["OG001","OG003"],"nonInferiorityType":"OTHER","nonInferiorityComment":"Fesomersen groups were compared to the placebo group using two-sided log-rank tests. Due to the exploratory nature of these analyses, no multiplicity adjustment was done. Cause-specific hazard ratio and corresponding 2-sided 95% confidence intervals, comparing the hazards for the event-of-interest in each of the Fesomersen groups with the placebo group were estimated based on three separate cause-specific Cox proportional hazards models as exploratory analysis.","pValue":"0.953","statisticalMethod":"Log Rank","paramType":"Cause specific Hazard ratio","paramValue":"0.95","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.19","ciUpperLimit":"4.72"},{"groupIds":["OG002","OG003"],"nonInferiorityType":"OTHER","nonInferiorityComment":"Fesomersen groups were compared to the placebo group using two-sided log-rank tests. Due to the exploratory nature of these analyses, no multiplicity adjustment was done. Cause-specific hazard ratio and corresponding 2-sided 95% confidence intervals, comparing the hazards for the event-of-interest in each of the Fesomersen groups with the placebo group were estimated based on three separate cause-specific Cox proportional hazards models as exploratory analysis.","pValue":"0.605","statisticalMethod":"Log Rank","paramType":"Cause specific Hazard ratio","paramValue":"0.63","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.10","ciUpperLimit":"3.75"}]},{"type":"SECONDARY","title":"Incidence of Composite of MB and CRNMB During the Main and Extended Treatment Periods and Within the On-treatment Time Window, as Assessed by Blinded CIAC","description":"MB is defined as symptomatic bleeding and: 1) Fatal bleeding, and/or; 2) Bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or; 3) Bleeding causing a fall in hemoglobin level of 20 g/L (2.0 g/dL) (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells. CRNMB is defined as any sign or symptom of hemorrhage that does not fit the criteria for the ISTH definition of major bleeding but does meet at least one of the following criteria: 1) Requiring medical intervention by a healthcare professional; 2) Leading to hospitalization or increased level of care; 3) Prompting a face-to-face evaluation. n/100 person-years: number of subjects with incident events divided by the cumulative at-risk time in the reference population, where a subject is no longer at risk once an incident event occurred.","populationDescription":"Safety analysis set (SAF) includes all randomized participants who received at least one dose of the study intervention according to actual treatment arm received.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"n/100 person-years","timeFrame":"Up to 48 weeks","groups":[{"id":"OG000","title":"Fesomersen 40 mg","description":"Participants received monthly subcutaneous treatment with 40 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG001","title":"Fesomersen 80 mg","description":"Participants received monthly subcutaneous treatment with 80 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG002","title":"Fesomersen 120 mg","description":"Participants received monthly subcutaneous treatment with 120 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG003","title":"Placebo","description":"Participants received monthly subcutaneous treatment with matching placebo to fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"76"},{"groupId":"OG003","value":"75"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","lowerLimit":"4.2","upperLimit":"19.7"},{"groupId":"OG001","value":"8.6","lowerLimit":"2.9","upperLimit":"16.7"},{"groupId":"OG002","value":"6.4","lowerLimit":"1.7","upperLimit":"13.3"},{"groupId":"OG003","value":"7.0","lowerLimit":"1.9","upperLimit":"14.8"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","nonInferiorityComment":"Fesomersen groups were compared to the placebo group using two-sided log-rank tests. Due to the exploratory nature of these analyses, no multiplicity adjustment was done. Cause-specific hazard ratio and corresponding 2-sided 95% confidence intervals, comparing the hazards for the event-of-interest in each of the Fesomersen groups with the placebo group were estimated based on three separate cause-specific Cox proportional hazards models as exploratory analysis.","pValue":"0.612","statisticalMethod":"Log Rank","paramType":"Cause specific Hazard ratio","paramValue":"1.45","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.34","ciUpperLimit":"6.08"},{"groupIds":["OG001","OG003"],"nonInferiorityType":"OTHER","nonInferiorityComment":"Fesomersen groups were compared to the placebo group using two-sided log-rank tests. Due to the exploratory nature of these analyses, no multiplicity adjustment was done. Cause-specific hazard ratio and corresponding 2-sided 95% confidence intervals, comparing the hazards for the event-of-interest in each of the Fesomersen groups with the placebo group were estimated based on three separate cause-specific Cox proportional hazards models as exploratory analysis.","pValue":"0.757","statisticalMethod":"Log Rank","paramType":"Cause specific Hazard ratio","paramValue":"1.27","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.28","ciUpperLimit":"5.66"},{"groupIds":["OG002","OG003"],"nonInferiorityType":"OTHER","nonInferiorityComment":"Fesomersen groups were compared to the placebo group using two-sided log-rank tests. Due to the exploratory nature of these analyses, no multiplicity adjustment was done. Cause-specific hazard ratio and corresponding 2-sided 95% confidence intervals, comparing the hazards for the event-of-interest in each of the Fesomersen groups with the placebo group were estimated based on three separate cause-specific Cox proportional hazards models as exploratory analysis.","pValue":"0.909","statisticalMethod":"Log Rank","paramType":"Cause specific Hazard ratio","paramValue":"0.91","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.18","ciUpperLimit":"4.52"}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Main Treatment Period and Within the On-treatment Time Window and Their Severity","description":"TEAEs were analyzed during the on-treatment time window within the main treatment period in the safety analysis set (SAF). Data observed from the randomization date until the end of the main treatment period. TEAEs were defined as events occurring after first study intervention administration and up to 20 weeks after last study intervention administration.","populationDescription":"Safety analysis set (SAF) includes all randomized participants who received at least one dose of the study intervention according to actual treatment arm received.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 24 weeks","groups":[{"id":"OG000","title":"Fesomersen 40 mg","description":"Participants received monthly subcutaneous treatment with 40 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG001","title":"Fesomersen 80 mg","description":"Participants received monthly subcutaneous treatment with 80 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG002","title":"Fesomersen 120 mg","description":"Participants received monthly subcutaneous treatment with 120 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG003","title":"Placebo","description":"Participants received monthly subcutaneous treatment with matching placebo to fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"76"},{"groupId":"OG003","value":"75"}]}],"classes":[{"title":"Any TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"55"}]}]},{"title":"Maximum intensity for any TEAE: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"27"}]}]},{"title":"Maximum intensity for any TEAE: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"19"}]}]},{"title":"Maximum intensity for any TEAE: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"9"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With TEAEs During the Main and Extended Treatment Periods and Within the On-treatment Time Window and Their Severity","description":"TEAEs were analyzed during during main and extended treatment periods in the safety analysis set (SAF). Data observed from the randomization date until the end of the extension treatment period. TEAEs were defined as events occurring after first study intervention administration and up to 20 weeks after last study intervention administration.","populationDescription":"Safety analysis set (SAF) includes all randomized participants who received at least one dose of the study intervention according to actual treatment arm received.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 48 weeks","groups":[{"id":"OG000","title":"Fesomersen 40 mg","description":"Participants received monthly subcutaneous treatment with 40 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG001","title":"Fesomersen 80 mg","description":"Participants received monthly subcutaneous treatment with 80 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG002","title":"Fesomersen 120 mg","description":"Participants received monthly subcutaneous treatment with 120 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG003","title":"Placebo","description":"Participants received monthly subcutaneous treatment with matching placebo to fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"76"},{"groupId":"OG003","value":"75"}]}],"classes":[{"title":"Any TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"62"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"56"}]}]},{"title":"Maximum intensity for any TEAE: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"26"}]}]},{"title":"Maximum intensity for any TEAE: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"30"},{"groupId":"OG003","value":"18"}]}]},{"title":"Maximum intensity for any TEAE: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"12"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With TEAEs During the Main and Extended Treatment Periods and Until 20 Weeks After the Last Study Intervention Dose and Their Severity","description":"TEAEs occurring from first study intervention intake until 20 weeks after last study intervention intake.","populationDescription":"Safety analysis set (SAF) includes all randomized participants who received at least one dose of the study intervention according to actual treatment arm received.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 48 weeks","groups":[{"id":"OG000","title":"Fesomersen 40 mg","description":"Participants received monthly subcutaneous treatment with 40 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG001","title":"Fesomersen 80 mg","description":"Participants received monthly subcutaneous treatment with 80 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG002","title":"Fesomersen 120 mg","description":"Participants received monthly subcutaneous treatment with 120 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG003","title":"Placebo","description":"Participants received monthly subcutaneous treatment with matching placebo to fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"76"},{"groupId":"OG003","value":"75"}]}],"classes":[{"title":"Any TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"62"},{"groupId":"OG003","value":"59"}]}]},{"title":"Maximum intensity for any TEAE: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"21"}]}]},{"title":"Maximum intensity for any TEAE: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"22"}]}]},{"title":"Maximum intensity for any TEAE: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"16"}]}]}]},{"type":"SECONDARY","title":"Trough Concentrations (Ctrough) of Three Dose Levels of Fesomersen","description":"Trough (pre-dose) fesomersen-equivalent plasma concentrations (Ctrough) for 3 dose levels of fesomersen were summarized descriptively by dose level and visit: Visit 12, Visit 14, Visit 16, Visit 18 (main treatment period). Ctrough was not measured for the placebo group.","populationDescription":"Pharmacokinetic analysis set (PKS) includes all fesomersen-treated participants with at least 1 PK sample in accordance with the PK sampling schedule and without deviation from the protocol that would interfere with the evaluation of the PK data were included in the PK analysis. Only those participants who have sample collection with data available at the specified time points were analyzed.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"At visits V12 (Day 57), V14 (Day 85), V16 (Day 113), V18 (Day 141)","groups":[{"id":"OG000","title":"Fesomersen 40 mg","description":"Participants received monthly subcutaneous treatment with 40 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG001","title":"Fesomersen 80 mg","description":"Participants received monthly subcutaneous treatment with 80 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG002","title":"Fesomersen 120 mg","description":"Participants received monthly subcutaneous treatment with 120 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"76"}]}],"classes":[{"title":"Visit 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"55"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.000454","spread":"118.753791"},{"groupId":"OG001","value":"0.000704","spread":"80.938271"},{"groupId":"OG002","value":"0.001186","spread":"76.691406"}]}]},{"title":"Visit 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.000490","spread":"92.511801"},{"groupId":"OG001","value":"0.000792","spread":"82.170296"},{"groupId":"OG002","value":"0.001246","spread":"97.530820"}]}]},{"title":"Visit 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.000572","spread":"85.974878"},{"groupId":"OG001","value":"0.000789","spread":"68.188121"},{"groupId":"OG002","value":"0.001346","spread":"81.805680"}]}]},{"title":"Visit 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"53"},{"groupId":"OG002","value":"59"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.000521","spread":"106.848825"},{"groupId":"OG001","value":"0.000828","spread":"91.024162"},{"groupId":"OG002","value":"0.001424","spread":"92.709743"}]}]}]},{"type":"SECONDARY","title":"Maximum Change in FXI (Coagulation Factor XI) Antigen Levels During the Main Treatment Period","description":"The secondary endpoint of change in FXI antigen levels during the main treatment period was an optional secondary endpoint only as mentioned in the integrated clinical protocol amendment version 3.0 and was not analyzed in this study as the FXI activity assay is sufficient to describe the effect on FXI level in plasma.","populationDescription":"Pharmacodynamic set (PDS) includes all participants with at least 1 PD sample in accordance with the PD sampling schedule and without deviation from the protocol that would interfere with the evaluation of the PD data were included in the PD analysis. Data were not collected for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to 24 weeks","groups":[{"id":"OG000","title":"Fesomersen 40 mg","description":"Participants received monthly subcutaneous treatment with 40 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG001","title":"Fesomersen 80 mg","description":"Participants received monthly subcutaneous treatment with 80 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG002","title":"Fesomersen 120 mg","description":"Participants received monthly subcutaneous treatment with 120 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG003","title":"Placebo","description":"Participants received monthly subcutaneous treatment with matching placebo to fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"classes":[{"title":"Baseline"},{"title":"Visit 5 (Day 1)"}]},{"type":"SECONDARY","title":"Maximum Change in FXI Activity Levels During the Main Treatment Period","description":"The FXIa activity was measured by a fluorogenic activated FXIa activity (AXIA) assay. Absolute change from baseline at each visit until Visit 22 (Day 169) are reported.","populationDescription":"Pharmacodynamic set (PDS) includes all participants with at least 1 PD sample in accordance with the PD sampling schedule and without deviation from the protocol that would interfere with the evaluation of the PD data were included in the PD analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"U/mL","timeFrame":"Baseline, Days 1 (Pre-Dose and 5 hours post-dose), 2, 8, 15, 22, 29 (Pre-dose and 5 hours post-dose), 43, 57 (Pre-dose), 71, 85 (Pre-dose), 113 (Pre-dose), 141 (Pre-dose),148, 155, 162, and 169 (Pre-dose)","groups":[{"id":"OG000","title":"Fesomersen 40 mg","description":"Participants received monthly subcutaneous treatment with 40 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG001","title":"Fesomersen 80 mg","description":"Participants received monthly subcutaneous treatment with 80 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG002","title":"Fesomersen 120 mg","description":"Participants received monthly subcutaneous treatment with 120 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."},{"id":"OG003","title":"Placebo","description":"Participants received monthly subcutaneous treatment with matching placebo to fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"76"},{"groupId":"OG003","value":"75"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"0.00","spread":"0.00"},{"groupId":"OG002","value":"0.00","spread":"0.00"},{"groupId":"OG003","value":"0.00","spread":"0.00"}]}]},{"title":"Visit 5 (Day 1): Pre-dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.06"},{"groupId":"OG001","value":"0.05","spread":"0.06"},{"groupId":"OG002","value":"0.05","spread":"0.05"},{"groupId":"OG003","value":"0.04","spread":"0.05"}]}]},{"title":"Visit 5 (Day 1): 5 Hours","categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.09"},{"groupId":"OG001","value":"0.11","spread":"0.12"},{"groupId":"OG002","value":"0.13","spread":"0.13"},{"groupId":"OG003","value":"0.10","spread":"0.08"}]}]},{"title":"Visit 6 (Day 2): 22 Hours","categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.11"},{"groupId":"OG001","value":"0.12","spread":"0.12"},{"groupId":"OG002","value":"0.15","spread":"0.13"},{"groupId":"OG003","value":"0.14","spread":"0.13"}]}]},{"title":"Visit 7 (Day 8)","categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":"0.15"},{"groupId":"OG001","value":"0.32","spread":"0.15"},{"groupId":"OG002","value":"0.43","spread":"0.18"},{"groupId":"OG003","value":"0.08","spread":"0.07"}]}]},{"title":"Visit 8 (Day 15)","categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":"0.23"},{"groupId":"OG001","value":"0.48","spread":"0.21"},{"groupId":"OG002","value":"0.61","spread":"0.24"},{"groupId":"OG003","value":"0.12","spread":"0.09"}]}]},{"title":"Visit 9 (Day 22)","categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":"0.26"},{"groupId":"OG001","value":"0.50","spread":"0.23"},{"groupId":"OG002","value":"0.63","spread":"0.25"},{"groupId":"OG003","value":"0.11","spread":"0.09"}]}]},{"title":"Visit 10 (Day 29): Pre-dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":"0.26"},{"groupId":"OG001","value":"0.44","spread":"0.21"},{"groupId":"OG002","value":"0.60","spread":"0.25"},{"groupId":"OG003","value":"0.09","spread":"0.07"}]}]},{"title":"Visit 10 (Day 29): 5 Hours","categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":"0.25"},{"groupId":"OG001","value":"0.43","spread":"0.22"},{"groupId":"OG002","value":"0.58","spread":"0.25"},{"groupId":"OG003","value":"0.12","spread":"0.14"}]}]},{"title":"Visit 11 (Day 43)","categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":"0.29"},{"groupId":"OG001","value":"0.59","spread":"0.25"},{"groupId":"OG002","value":"0.76","spread":"0.27"},{"groupId":"OG003","value":"0.09","spread":"0.08"}]}]},{"title":"Visit 12 (Day 57): Pre-dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":"0.26"},{"groupId":"OG001","value":"0.55","spread":"0.24"},{"groupId":"OG002","value":"0.69","spread":"0.28"},{"groupId":"OG003","value":"0.11","spread":"0.10"}]}]},{"title":"Visit 13 (Day 71)","categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":"0.26"},{"groupId":"OG001","value":"0.66","spread":"0.24"},{"groupId":"OG002","value":"0.76","spread":"0.25"},{"groupId":"OG003","value":"0.15","spread":"0.13"}]}]},{"title":"Visit 14 (Day 85): Pre-dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":"0.27"},{"groupId":"OG001","value":"0.59","spread":"0.26"},{"groupId":"OG002","value":"0.72","spread":"0.24"},{"groupId":"OG003","value":"0.14","spread":"0.12"}]}]},{"title":"Visit 16 (Day 113): Pre-dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":"0.26"},{"groupId":"OG001","value":"0.57","spread":"0.28"},{"groupId":"OG002","value":"0.75","spread":"0.25"},{"groupId":"OG003","value":"0.16","spread":"0.16"}]}]},{"title":"Visit 18 (Day 141): Pre-dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":"0.27"},{"groupId":"OG001","value":"0.56","spread":"0.28"},{"groupId":"OG002","value":"0.72","spread":"0.25"},{"groupId":"OG003","value":"0.12","spread":"0.09"}]}]},{"title":"Visit 19 (Day 148)","categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":"0.27"},{"groupId":"OG001","value":"0.63","spread":"0.29"},{"groupId":"OG002","value":"0.76","spread":"0.26"},{"groupId":"OG003","value":"0.15","spread":"0.16"}]}]},{"title":"Visit 20 (Day 155)","categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":"0.28"},{"groupId":"OG001","value":"0.65","spread":"0.29"},{"groupId":"OG002","value":"0.77","spread":"0.25"},{"groupId":"OG003","value":"0.15","spread":"0.17"}]}]},{"title":"Visit 21 (Day 162)","categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.30"},{"groupId":"OG001","value":"0.64","spread":"0.28"},{"groupId":"OG002","value":"0.75","spread":"0.26"},{"groupId":"OG003","value":"0.16","spread":"0.20"}]}]},{"title":"Visit 22 (Day 169): Pre-dose","categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":"0.29"},{"groupId":"OG001","value":"0.59","spread":"0.28"},{"groupId":"OG002","value":"0.73","spread":"0.25"},{"groupId":"OG003","value":"0.17","spread":"0.21"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From first study intervention up to 64 Weeks.","description":"Adverse event reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact, up to 64 Weeks.","eventGroups":[{"id":"EG000","title":"Fesomersen 40 mg","description":"Participants received monthly subcutaneous treatment with 40 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide.","deathsNumAffected":2,"deathsNumAtRisk":77,"seriousNumAffected":19,"seriousNumAtRisk":77,"otherNumAffected":31,"otherNumAtRisk":77},{"id":"EG001","title":"Fesomersen 80 mg","description":"Participants received monthly subcutaneous treatment with 80 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide.","deathsNumAffected":1,"deathsNumAtRisk":79,"seriousNumAffected":18,"seriousNumAtRisk":79,"otherNumAffected":27,"otherNumAtRisk":79},{"id":"EG002","title":"Fesomersen 120 mg","description":"Participants received monthly subcutaneous treatment with 120 mg fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide.","deathsNumAffected":2,"deathsNumAtRisk":76,"seriousNumAffected":17,"seriousNumAtRisk":76,"otherNumAffected":30,"otherNumAtRisk":76},{"id":"EG003","title":"Placebo","description":"Participants received monthly subcutaneous treatment with matching placebo to fesomersen (Factor XI LICA). LICA=Ligand conjugated antisense oligonucleotide.","deathsNumAffected":7,"deathsNumAtRisk":75,"seriousNumAffected":20,"seriousNumAtRisk":75,"otherNumAffected":21,"otherNumAtRisk":75}],"seriousEvents":[{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Spleen ischaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Ventricular fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Bradyarrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Abdominal adhesions","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Duodenal ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Intestinal ischaemia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Large intestine perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Small intestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Obstructive pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Device related thrombosis","organSystem":"General disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Bile duct stone","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Cholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Hepatic ischaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":76},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":75}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Gangrene","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Orchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Peritonitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Staphylococcal bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Coronavirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Sepsis syndrome","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Staphylococcal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Vascular access site infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":76},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":75}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":77},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":79},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Arteriovenous fistula thrombosis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":76},{"groupId":"EG003","numEvents":7,"numAffected":3,"numAtRisk":75}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Shunt occlusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Arteriovenous graft thrombosis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Arteriovenous fistula site complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Arteriovenous graft site haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Shunt stenosis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Vascular graft thrombosis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Delayed graft function","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Arteriovenous graft site pseudoaneurysm","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Transplant evaluation","organSystem":"Investigations","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Klebsiella test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Rotator cuff syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Endometrial cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Pancreatic neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Carotid artery stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Loss of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Post cardiac arrest syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Renal transplant","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":77},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Subclavian vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Peripheral arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Peripheral artery thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Superficial vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":77},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":77},{"groupId":"EG001","numEvents":9,"numAffected":4,"numAtRisk":79},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":76},{"groupId":"EG003","numEvents":5,"numAffected":4,"numAtRisk":75}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":77},{"groupId":"EG001","numEvents":13,"numAffected":7,"numAtRisk":79},{"groupId":"EG002","numEvents":11,"numAffected":7,"numAtRisk":76},{"groupId":"EG003","numEvents":4,"numAffected":2,"numAtRisk":75}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":5,"numAtRisk":77},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":79},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":76},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":75}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":77},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":79},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":76},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":75}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":77},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":79},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":76},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":75}]},{"term":"N-terminal prohormone brain natriuretic peptide increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":77},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":79},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":76},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":75}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":77},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":79},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":76},{"groupId":"EG003","numEvents":5,"numAffected":2,"numAtRisk":75}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":4,"numAtRisk":77},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":79},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":76},{"groupId":"EG003","numEvents":13,"numAffected":3,"numAtRisk":75}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":77},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":79},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":77},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":79},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":76},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":75}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":77},{"groupId":"EG001","numEvents":9,"numAffected":5,"numAtRisk":79},{"groupId":"EG002","numEvents":8,"numAffected":6,"numAtRisk":76},{"groupId":"EG003","numEvents":8,"numAffected":7,"numAtRisk":75}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (25.0)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":6,"numAtRisk":77},{"groupId":"EG001","numEvents":12,"numAffected":4,"numAtRisk":79},{"groupId":"EG002","numEvents":12,"numAffected":8,"numAtRisk":76},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":75}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The results of this study may be published or presented at scientific meetings. If this is foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. This allows the sponsor to protect proprietary information and to provide comments."},"pointOfContact":{"title":"Therapeutic Area Head","organization":"Bayer AG","email":"clinical-trials-contact@bayer.com","phone":"(+) 1-888-8422937"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-07-07","uploadDate":"2023-05-06T05:20","filename":"Prot_000.pdf","size":1038086},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2022-05-31","uploadDate":"2023-05-06T05:20","filename":"SAP_001.pdf","size":681060}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2023-06-02","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D000007674","term":"Kidney Diseases"},{"id":"D000007676","term":"Kidney Failure, Chronic"}],"ancestors":[{"id":"D000014570","term":"Urologic Diseases"},{"id":"D000052776","term":"Female Urogenital Diseases"},{"id":"D000005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D000052801","term":"Male Urogenital Diseases"},{"id":"D000051436","term":"Renal Insufficiency, Chronic"},{"id":"D000051437","term":"Renal Insufficiency"},{"id":"D000002908","term":"Chronic Disease"},{"id":"D000020969","term":"Disease Attributes"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10388","name":"Kidney Diseases","asFound":"Renal Disease","relevance":"HIGH"},{"id":"M10389","name":"Kidney Failure, Chronic","asFound":"End Stage Renal Disease","relevance":"HIGH"},{"id":"M11845","name":"Myocardial Infarction","relevance":"LOW"},{"id":"M26408","name":"Renal Insufficiency","relevance":"LOW"},{"id":"M17009","name":"Urologic Diseases","relevance":"LOW"},{"id":"M2876","name":"Urogenital Diseases","relevance":"LOW"},{"id":"M26783","name":"Female Urogenital Diseases","relevance":"LOW"},{"id":"M13817","name":"Pregnancy Complications","relevance":"LOW"},{"id":"M8089","name":"Female Urogenital Diseases and Pregnancy Complications","relevance":"LOW"},{"id":"M26785","name":"Male Urogenital Diseases","relevance":"LOW"},{"id":"M26407","name":"Renal Insufficiency, Chronic","relevance":"LOW"},{"id":"M5837","name":"Chronic Disease","relevance":"LOW"},{"id":"M22390","name":"Disease Attributes","relevance":"LOW"},{"id":"T1303","name":"Chronic Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BXS","name":"Urinary Tract, Sexual Organs, and Pregnancy Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":true}